Analyst Suggests MannKind Could Receive FDA Approval for Afrezza If Trials Pass

By: Benzinga
About one hour after the open MannKind (NASDAQ: MNKD ) shares are trading down about 4 percent despite some bullish views from an analyst at Summer Street. The analyst believes MannKind's new drug Afrezza is ready for approval by the FDA -- with one catch: the drug needs to pass
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.